Download PDFPDF
Why are anogenital warts diagnoses decreasing in the UK: bivalent human papillomavirus (HPV) vaccine cross-protection or failure to examine?
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Why are anogenital warts diagnoses decreasing: Can we explain sex- and age-specific decreases?
    • David Mesher, Scientist
    • Other Contributors:
      • Gwenda Hughes and Kate Soldan

    The audit by Clarke et al of 106 patients provides a useful estimate of the percentage of anogenital warts among GUM clinic attenders that the patient had not noticed (in 2010), at 12.3%[1]. They suggest that failure to examine these patients may have accounted for a considerable proportion of the reduction in anogenital warts diagnoses in GUM seen in England between 2008 and 2012, of 8% among males and females of all age...

    Show More
    Conflict of Interest:
    None declared.